Intellia Therapeutics, Inc. (NASDAQ:NTLA) just released its latest quarterly results and things are looking bullish. Revenues of US$17m beat estimates by a substantial 39% margin. Unfortunately, ...

Q1 2025 Management View CEO John Leonard emphasized that Intellia has made significant progress early in 2025, achieving two key milestones: dosing the first patient in Phase 3 studies for hereditary ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts have sharply ...

Intellia will present additional data from the ongoing Phase 1/2 study in an oral presentation at the European Academy of ...

Intellia Therapeutics, Inc. announced key operational and financial updates for the first quarter of 2025, highlighting significant progress in its clinical trials. The company is on track to ...

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

Analysts expect Intellia Therapeutics to report an earnings per share (EPS) of $-1.27. Anticipation surrounds Intellia ...

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...